Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine.
We compared immune responses to intranasal and intramuscular DNA vaccinations against human immunodeficiency virus type 1 with monophosphoryl lipid A (MPL) used as an adjuvant. Both routes of vaccination resulted in similar levels of cell-mediated immunity, but the intestinal secretory immunoglobulin A response was higher following intranasal immunization than after intramuscular immunization. MPL demonstrated its adjuvanticity in vaccination by both routes.
Sasaki
S
S
Department of Bacteriology, Yokohama City University School of Medicine, Yokohama, Japan.
Hamajima
K
K
Fukushima
J
J
Ihata
A
A
Ishii
N
N
Gorai
I
I
Hirahara
F
F
Mohri
H
H
Okuda
K
K
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000281:Administration, Intranasal; D000818:Animals; D002772:Cholera Toxin / Q000008:administration & dosage; D015483:HIV Antibodies / Q000096:biosynthesis; D015497:HIV-1 / Q000276:immunology*; D006968:Hypersensitivity, Delayed; D018928:Immunity, Mucosal; D007114:Immunization; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis; D007273:Injections, Intramuscular; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives*; D051379:Mice; D008807:Mice, Inbred BALB C; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
D016915:AIDS Vaccines; D015483:HIV Antibodies; D007071:Immunoglobulin A, Secretory; D008050:Lipid A; D019444:Vaccines, DNA; D002772:Cholera Toxin; C048436:monophosphoryl lipid A